Pneumagen is developing glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer.

Latest news and events

Oct 15, 2019
Pneumagen Ltd Demonstrates Preclinical Proof-of-Concept in Oncology for Neumonco, a Novel Carbohydrate Binding Module
Nov 11, 2019
BioEurope
Nov 14, 2019
RSVVW 2019

Meet the team